Serotonin Syndrome Market Research Report- Forecast till 2027

Serotonin Syndrome Market information: by drug treatment (serotonin antagonists, supportive care (Muscle relaxants, sedatives, anti-hyperthermics, antihypertensive, others), gastrointestinal decontamination, others) by end users (hospitals, point of care, others) - Forecast till 2027

ID: MRFR/Pharma/2743-HCR | February 2021 | Region: Global | 90 pages

Serotonin Syndrome Market Scenario:


Serotonin syndrome is a group of symptoms such as high body temperature, agitation, increased reflexes, tremor, sweating, dilated pupils, diarrhoea etc. due to use of serotonergic drugs. Serious complications such as seizures and extensive muscle breakdown may occur which may lead to death. The 1984, Libby Zion case is an example of death from serotonin syndrome. Serotonin syndrome is typically caused by synergistic effect of two or more serotonergic drugs which generally include selective serotonin reuptake inhibitor (SSRI), serotonin norepinephrine reuptake inhibitor (SNRI), monoamine oxidase inhibitor (MAOI), tricyclic antidepressants (TCAs), amphetamines etc. Other drugs with a high propensity of causing serotonin syndrome are dextromethorphan, buspirone, L-tryptophan, St. John's wort, metoclopramide, ondansetron etc. There is no laboratory test to confirm the diagnosis of serotonin syndrome.

The treatment for serotonin syndrome consists of discontinuing medications contributing to the condition. For serious cases, other treatments for managing associated symptoms may be used. For serious cases with a threat to life gastrointestinal decontamination using activated charcoal is performed. Sedatives such as benzodiazepines are used for agitated patients. High fever is a common symptom of serotonin syndrome which reaches extremely high temperatures greater than forty centigrade. To control hyperthermia cooling measures may be needed. Serotonin antagonist such as cyproheptadine may be needed.


The serotonin syndrome market restraints are the low number of cases and equally low number of fatalities associated with the syndrome with less than 1% cases consuming serotonin syndrome causing drugs developing the diseases. Mild symptoms occur in about 15% of SSRI overdoses.


Considering all these factors, the serotonin syndrome market is expected to reach USD 400 million by the end of 2023, serotonin syndrome market is projected to growing at a CAGR of ~ 2.3 % during 2017-2023.


 


Sources: Mayo Clinic, MRFR Analysis.


Intended Audience



  • Global Serotonin syndrome diagnosis and treatment solutions, manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Figure 1  Serotonin syndrome market by Surgery, 2016 (% Market Share)



Segments:
The serotonin syndrome market is segmented on the basis of drug treatment, and end users. Based on drug treatment, the market has been segmented as serotonin antagonists, supportive care (Muscle relaxants, the control of autonomic instability, anti-hyperthermics, antihypertensive and others. Based on the end users, the market has been segmented as hospitals, point of care and others.


Regional analysis
US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for
global serotonin syndrome diagnosis and treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.

Key players of Serotonin syndrome market:
Key players profiled in the report are
AstraZeneca Plc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc. and Sanofi S.A., Ciron Drugs & Pharmaceuticals Pvt. Ltd. and others. The report for Serotonin syndrome market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 400 Million
  • 2027: Significant Value
  •   CAGR   2.3% (2017-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Drug Treatment, and End Users
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   AstraZeneca Plc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc. and Sanofi S.A., Ciron Drugs & Pharmaceuticals Pvt. Ltd. and others
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Growing advancements in the development of novel drugs
  • Growing health infrastructure in several nations


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Serotonin syndrome market is expected to exhibit a CAGR of 2.3% from 2017 to 2023.

    Serotonin syndrome market size can reach USD 400 million by 2023.

    North America can dominate the global serotonin syndrome market till 2023.

    Asia Pacific (APAC) has the highest potential for growth in the global serotonin syndrome market.

    AstraZeneca Plc., Johnson & Johnson, Merck & Co., Inc., Forest Laboratories Inc., Pfizer, Inc., Sanofi S., Eli Lilly and Company, Ciron Drugs & Pharmaceuticals Pvt. Ltd., and GlaxoSmithKline plc are notable players of the global serotonin syndrome market.

    1. Introduction

    1.1 Definition

    1.2 scope of study

    1.2.1 Research Objective

    1.2.2 Assumptions & Limitations

    1.2.2.1 Assumptions

    1.2.2.2 Limitations

    1.3 Market Structure:

    2. Research Methodology

    2.1 Research Process:

    2.2 Primary Research

    2.3 Secondary Research:

    3. Market dynamics

    3.1 Drivers

    3.2 Restraints

    3.3 Opportunities

    3.4 Macroeconomic Indicators

    4. Market factor analysis

    4.1 Porters Five Forces Model

    4.2 Bargaining Power Of Suppliers

    4.3 Bargaining Power Of Buyers

    4.4 Threat Of New Entrants

    4.5 Threat Of Substitutes

    4.6 Intensity Of Rivalry

    5. Global Serotonin Syndrome Market, by Drug Treatment

    5.1 Serotonin Antagonists

    5.2 Supportive Care

    5.2.1 Muscle Relaxants

    5.2.2 Sedatives

    5.2.3 Anti-Hyperthermics

    5.2.4 Antihypertensive

    5.2.5 Others

    5.3 Gastrointestinal Decontamination

    5.4 Others

    6. Global Serotonin Syndrome Market, By End Users

    6.1 Hospitals

    6.2 Point Of Care

    6.3 Others

    7. Global Serotonin Syndrome Market, By Region

    7.1 North America

    7.1.1 Introduction

    7.2 Europe

    7.2.1 Introduction

    7.3 Asia-Pacific

    7.3.1 Introduction

    7.4 Middle East & Africa

    7.4.1 Introduction

    8. Competitive landscape

    8.1 Major Strategies Adopted By Market Players

    8.1.1 Strategic Partnership

    8.1.2 Merger & Acquisition

    9. Company profile

    9.1 AstraZeneca Plc.

    9.1.1 Overview

    9.1.2 Product Overview

    9.1.3 Financials

    9.1.4 Key Developments

    9.2 Eli Lilly and Company

    9.2.1 Overview

    9.2.2 Product Overview

    9.2.3 Financials

    9.2.4 Key Developments

    9.3 Forest Laboratories Inc.

    9.3.1 Overview

    9.3.2 Product Overview

    9.3.3 Financials

    9.3.4 Key Development

    9.4 GlaxoSmithKline plc.

    9.4.1 Overview

    9.4.2 Product Overview

    9.4.3 Financials

    9.4.4 Key Developments

    9.5 Johnson & Johnson

    9.5.1 Overview

    9.5.2 Product Overview

    9.5.3 Financials

    9.5.4 Key Developments

    9.6 Pfizer, Inc.

    9.6.1 Overview

    9.6.2 Product Overview

    9.6.3 Financials

    9.6.4 Key Developments

    9.7 Sanofi S.A.

    9.7.1 Overview

    9.7.2 Product Overview

    9.7.3 Financials

    9.7.4 Key Developments

    9.8 Ciron Drugs & Pharmaceuticals Pvt. Ltd.

    9.8.1 Overview

    9.8.2 Product Overview

    9.8.3 Financials

    9.8.4 Key Developments

    9.9 Merck & Co., Inc.

    9.9.1 Overview

    9.9.2 Product Overview

    9.9.3 Financials

    9.9.4 Key Developments

    9.10 Other

    10. Conclusion

    10.1 Key Findings

    10.1.1 From Ceo’s Viewpoint

    10.1.2 Unmet Needs Of The Market

    10.2 Key Companies To Watch

    10.3 Prediction Of Serotonin Syndrome Treatment Industry

    11. Appendix